FDA-Approved Study to Investigate Therapeutic Potential of Mushroom-Derived Psilocin and Psilocybin

Ganjapreneur
By Lukas BarfieldJul 7, 2022, 2:31 pm209 pts
Filament Health, a clinical-stage natural psychedelic drug development company, has announced the start of a first-of-its-kind study in which psilocin and psilocybin derived from mushrooms — rather than constituents created in a lab — will be administered to patients. Overseen by Dr. Joshua Woolley at…

Read Article Share
Share Article
- email
- twitter
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

4Front Ventures’ Receivership Proceedings Progress; Board Members Resign 65

Embracing Marijuana Legalization Could Help GOP Win Over More Young Voters, Trump’s First Attorney General Pick Suggests 64

How private credit built – and will continue to sustain – the cannabis industry 56

Thailand Will Reclassify Cannabis as Narcotic 56

High Tide Opening 2 Canna Cabana Dispensaries in Toronto, Winnipeg 52

Federal Court Rules Arkansas’ Ban on Hemp-Derived THC Can Move Forward 51

AYR Wellness Has No Estimate for Q1 2025 Interim Filings; Trading Remains on Hold 47

Cannabis brand reaches unprecedented status 46

About NewsBudz

NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates.

Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.

Whether you're interested in policy reform, health research, cannabis business, CBD, delta 9 products or lifestyle stories, NewsBudz keeps you informed and connected. Accessible on the web and mobile, NewsBudz makes it easy to explore, read, and share cannabis news anytime, anywhere.